Arrest Defective 1 Autoacetylation Is a Critical Step in Its Ability to Stimulate Cancer Cell Proliferation

Authors:
  • JCJong-Ho Cha
    Jong-Ho Cha
  • JPJi-Hyeon Park
    Ji-Hyeon Park
  • CJChul-Ho Jeong
    Chul-Ho Jeong
  • ZPZee-Yong Park
    Zee-Yong Park
  • HLHye-Suk Lee
    Hye-Suk Lee
  • SOSeung Hyun Oh
    Seung Hyun Oh
  • JKJu-Hee Kang
    Ju-Hee Kang
  • SSSe Won Suh
    Se Won Suh
  • KKKyoung Hoon Kim
    Kyoung Hoon Kim
  • JHJun Yong Ha
    Jun Yong Ha
  • SHSang Hee Han
    Sang Hee Han

Abstract
The N-acetyltransferase arrest defective 1 (ARD1) is an important regulator of cell growth and differentiation that has emerged recently as a critical molecule in cancer progression. However, the regulation of the enzymatic and biological activities of human ARD1 (hARD1) in cancer is presently poorly understood. Here, we report that hARD1 undergoes autoacetylation and that this modification is essential for its functional activation. Using liquid chromatography-tandem mass spectrometry and site-directed mutational analyses, we identified K136 residue as an autoacetylation target site. K136R mutation abolished the ability of hARD1 to promote cancer cell growth in vitro and tumor xenograft growth in vivo. Mechanistic investigations revealed that hARD1 autoacetylation stimulated cyclin D1 expression through activation of the transcription factors β-catenin and activator protein-1. Our results show that hARD1 autoacetylation is critical for its activation and its ability to stimulate cancer cell proliferation and tumorigenesis. Cancer Res; 70(11); 4422–32. ©2010 AACR.